Other equities analysts have also recently issued reports about the company. ValuEngine cut Neurocrine Biosciences from a hold rating to a sell rating in a report on Thursday, November 14th. Zacks Investment Research lowered Neurocrine Biosciences from a buy rating to a hold rating in a report on Wednesday, November 20th. Royal Bank of Canada set a $118.00 price target on Neurocrine Biosciences and gave the stock a buy rating in a research report on Friday, September 6th. Piper Jaffray Companies raised their price objective on Neurocrine Biosciences from $111.00 to $116.00 in a research note on Tuesday, November 5th. Finally, TheStreet raised Neurocrine Biosciences from a c+ rating to a b rating in a research report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Neurocrine Biosciences has an average rating of Buy and a consensus target price of $105.72.
NBIX stock traded up $0.33 during midday trading on Thursday, reaching $116.81. 762,008 shares of the company’s stock traded hands, compared to its average volume of 826,888. Neurocrine Biosciences has a 52-week low of $64.72 and a 52-week high of $119.65. The stock has a market cap of $10.76 billion, a P/E ratio of 530.95, a PEG ratio of 5.90 and a beta of 1.24. The company has a current ratio of 7.08, a quick ratio of 6.99 and a debt-to-equity ratio of 0.83. The stock’s 50-day moving average is $107.65 and its 200 day moving average is $94.38.
In related news, insider Malcolm Lloyd-Smith sold 9,956 shares of the firm’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $90.85, for a total transaction of $904,502.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Julie Cooke sold 987 shares of Neurocrine Biosciences stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $88.56, for a total transaction of $87,408.72. The disclosure for this sale can be found here. Insiders have sold a total of 47,776 shares of company stock worth $4,936,638 in the last three months. 4.30% of the stock is owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the business. Comerica Bank lifted its position in shares of Neurocrine Biosciences by 3.3% in the third quarter. Comerica Bank now owns 3,933 shares of the company’s stock worth $386,000 after buying an additional 125 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Neurocrine Biosciences by 2.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 6,265 shares of the company’s stock valued at $565,000 after buying an additional 135 shares in the last quarter. M&T Bank Corp grew its holdings in Neurocrine Biosciences by 4.7% during the 2nd quarter. M&T Bank Corp now owns 3,377 shares of the company’s stock valued at $286,000 after buying an additional 153 shares in the last quarter. JGP Global Gestao de Recursos Ltda. increased its stake in Neurocrine Biosciences by 5.6% in the 3rd quarter. JGP Global Gestao de Recursos Ltda. now owns 3,097 shares of the company’s stock worth $279,000 after acquiring an additional 163 shares during the last quarter. Finally, Virginia Retirement Systems ET AL increased its stake in Neurocrine Biosciences by 1.2% in the 3rd quarter. Virginia Retirement Systems ET AL now owns 17,000 shares of the company’s stock worth $1,532,000 after acquiring an additional 200 shares during the last quarter. Institutional investors and hedge funds own 97.13% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.